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Background: Serum quantitative hepatitis B surface antigen (HBsAg) levels may be an important predictor of
hepatitis B e antigen (HBeAg) seroconversion (SC) in HBeAg-positive chronic hepatitis B (CHB) patients during
antiviral treatment. The pattern of HBsAg variation in CHB patients either with or without SC following tenofovir
disoproxil fumarate (TDF) treatment is not clearly understood.
Methods: Twenty patients with full experimental data were enrolled, and liver biochemistry, serum HBV DNA, and
circulating CD4+CD25+ regulatory T cell (Treg) levels were determined at baseline and every 12weeks after the
initiation of TDF treatment (for a total of 96weeks). In addition, the relationship between HBsAg or HBeAg and
alanine aminotransferase (ALT), HBV DNA and Treg levels in SC and non-SC patients was analyzed.
Results: In all, 9 patients had undergone HBeAg seroconversion by week 72 of TDF treatment, and biochemical
and virological indexes and Treg percentages declined to normal levels. Furthermore, the positive correlation
between HBsAg and ALT, HBV DNA and Treg levels was significant for SC patients, but not for non-SC patients.
However, for HBeAg, significant positive correlations were or not observed for both SC and non-SC patients.
Conclusions: The quantitation of HBsAg is a more useful indicator than HBeAg for distinguishing SC and non-SC
patients during TDF treatment. Moreover, HBsAg may be related to immune regulatory property of CHB patients
during antiviral treatment.
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Hepatitis B virus (HBV) infection remains a serious
health problem that currently affects approximately 350
to 400 million people worldwide. Chronic hepatitis B
(CHB) is closely association with the morbidity of liver cir-
rhosis, liver failure, and hepatocellular carcinoma (HCC)
[1]. Antiviral therapy against HBV plays a pivotal role in de-
termining the outcome of CHB. Effective antiviral therapy
for CHB would achieve control of viral replication, ALT
normalization, HBeAg loss and seroconversion, and a small
number of patients may even achieve HBsAg clearance
and seroconversion [2,3]. HBeAg seroconversion (SC) is* Correspondence: ljli@zju.edu.cn
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unless otherwise stated.associated with a reduced incidence of progressive liver in-
flammation, cirrhosis, and failure and HCC [4-6]. CHB
patients undergoing SC usually become inactive HBsAg
carriers [5]. However, during antiviral therapy, CHB pa-
tients who have undergone the potent suppression of HBV
replication do not always induce SC, even though liver in-
flammation is controlled. Patients who do not experience
SC frequently develop reactivation with high levels of HBV
replication, and liver inflammation resumes when antiviral
drugs are stopped [7].
The covalently closed circular DNA (cccDNA) of HBV
plays a major role in viral persistence, and its clearance
is thought to be the limiting factor for the elimination of
infection. Serum HBsAg levels are known to reflect the
presence of cccDNA in the liver, and a reduction in
HBsAg levels correlates well with cccDNA levels [8].
HBsAg clearance from the serum approximates clinicald. This is an Open Access article distributed under the terms of the Creative
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dynamics of HBsAg decline have recently been described
in patients treated with standard interferon (IFN), pegy-
lated interferon (PEG-IFN), entecavir (ENV), and adefo-
vir (ADV) monotherapy [9-11]. However, the dynamic
pattern of serum HBsAg levels in HBeAg-positive CHB
patients who have or have not undergone SC following
TDF treatment has not been well described. In addition,
the relationship between variations in HBsAg levels and
ALT, HBV DNA, and circulation Treg percentages have
poorly addressed as well [12].
In the present study, we aimed to determine the dy-
namic profile of serum HBsAg levels in HBeAg-positive
CHB patients who did or did not undergo HBeAg sero-
conversion following TDF therapy, and its correlation
with biochemical, virological and immunological param-
eters during the treatment period.Materials and methods
Subjects and blood samples
A total of 78 outpatients with CHB were enrolled from
the Department of Infectious Disease, the First Affiliated
Hospital, College of Medicine, Zhejiang University between
November 2011 and February 2012. All patients were sero-
positive for HBsAg and HBeAg. They were 57 men and 21
women (age, mean ± STD, 33.1 ± 8.2 years) without concur-
rent other infectious diseases and autoimmune liver dis-
eases. At baseline, their HBV-DNA loads were more than
1 × 106 copies/ml (range, 1.5 × 107 – 6.2 × 109 copies/
ml) and ALT levels were twice (range, 112 – 452 U/L)
the upper limit of the normal levels. The average level
of HBsAg is 3.75 ± 0.68 (log10, IU/ml, mean ± STD).
For the following reasons, the enrolled CHB patients
could not be contacted (31 patients), switched to other
nucleotide analogues (entecavir, adefovir) treatment
(15 patients) due to the cost, or dropped out during
the TDF treatment (12 patients) for unknown reasons,
ultimately, only 20 CHB patients were followed serially
with protocol visits for 96 weeks continuously during
the course of TDF treatment with a daily dose of
300 mg.
The twenty HBeAg-positive CHB patients were classi-
fied into SC (n = 9) or non-SC (n = 11) groups, depend-
ing on whether they had undergone SC by week 72 of
TDF treatment. Subjects with CHB fulfilled the defini-
tions from Hou’s report [13] and The guideline of pre-
vention and treatment for chronic hepatitis B (2010
version) [14]. In addition, exclusion criteria were de-
scribed in our previous report [15]. Our study con-
formed to the ethical guidelines of the Declaration of
Helsinki, and informed consent was obtained from all
patients prior to enrollment. The First Affiliated Hos-
pital, College of Medicine, Zhejiang University medicalethics committee approved all procedures involving hu-
man subjects.
Assessment of biochemical, serological and virological
parameters
Patients visited the outpatient clinic every 12weeks for
routine examination and laboratory assessment. Routine
liver biochemistry, serological HBV parameters, and
quantitation of HBeAg and HBsAg levels were per-
formed at baseline and during all follow-up visits. Serum
ALT, Albumin (ALB), and total Bilirubin (TBiL) were de-
termined using an automatic biochemical analyzer
(AEROSET, Abbott, Chicago, IL, USA). Determination
of HBeAg and HBeAb (anti-HBe) status was performed
using a commercially available enzyme immunoassay.
For measurement of HBsAg and HBsAb, samples were
analyzed using commercial enzyme immunoassay kits
(Kewei Diagnostic, Beijing, China) according to the man-
ufacturer’s instructions. The serum HBV DNA level was
quantified using a Roche second-generation real-time
PCR machine (Cobas Ampfiprep/Cobes Taclman) with a
detection limit of 116 copies/ml according to the manu-
facturer’s instruction. HBV genotypes were determined
with sequence detection via PCR, and PCR products
were directly sequenced with an HBV Genotype Real
Time PCR kit (ZJ Bio-Tech, Shanghai, China) and run
on a MegaBACE™ 500 according to the manufacturer’s
instructions, as has been previously described in more
detail [16].
The above indicators were quantified in the clinical la-
boratory center of the First Affiliated Hospital, College
of Medicine, Zhejiang University.
Flow cytometric analysis of Treg percentage
The percentage of CD4+CD25+ regulatory T cells (Treg)
in CD4+ T cells was determined using flow cytometric
analysis, which was described in our previously protocol
[15].
Statistical Analysis
All data were analyzed using SPSS software version 19.0
(SPSS Inc., Chicago, IL, USA). Continuous variables
were analyzed using a Mann–Whitney test or Kruskal–
Wallis test. Paired-related data were analyzed using the
Wilcoxon paired test. The correlation between two pa-
rameters was determined using Spearman’s bivariate
correlation. Categorical variables were analyzed using a
χ2-test or Fisher’s exact test. A P value of <0.05 was
considered statistically significant.
Results
Patient characteristics and laboratory data at the time of
study entry (baseline) and at weeks 24 and 72 (time
points for the beginning and end of SC) are summarized
Figure 1 Changing characteristic of HBsAg in SC or non-SC
patients during treatment. The changing profile of serum HBsAg
(log10 IU/ml) level of each patient was classified to SC (A) or non-SC
patients (B) during TDF treatment for 96 weeks.
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levels from baseline to week 24 after commencing TDF
(4.15 vs. 3.15, log10 IU/ml, P < 0.001), and this decline
was observed in SC but not in non-SC patients. More-
over, there was a significant reduction in ALT levels
from weeks 24 to 72 during TDF treatment (29.7 vs.
19.4 U/L, P = 0.03) as was observed in just SC patients.
In addition, no other liver-related complications oc-
curred during treatment, and no serious adverse events
were identified. None of the patients experienced clear-
ance of HBsAg during the course of therapy.
Changing HBsAg level in SC and non-SC patients
We performed longitudinal analysis of HBsAg (log10
IU/ml) in peripheral blood in the SC and non-SC groups
during 96 weeks of treatment with TDF. We found that
the HBsAg content for each patient consistently declined
over the course of 96 weeks of antiviral treatment period
in the SC group (Figure 1A), which was different from
the pattern of fluctuating decline in HBsAg levels in the
non-SC group (Figure 1B). Furthermore, there were no
significant differences between the SC and non-SC
groups in the mean HBsAg levels at baseline or each treat-
ment time point over the course of 96 weeks (Additional
file 1: Figure S1). However, mean HBsAg was significantly
different between the baseline and at week 12 in SC pa-
tients, but not in the non-SC group (Additional file 2:
Figure S2).
The relationship between serum HBsAg and HBeAg and
ALT levels in SC and non-SC patients
In SC patients, there was significant reduction in the
serum ALT level from baseline to week 12 (mean,
240.22 to 47.44 U/L). In addition, there was a continuedTable 1 Patient characteristics and laboratory values at basel
Characteristic SC
Baseline 24W
Age (years) 29.8 ± 8.9 -
Gender (M/F) 7/2 -
ALT (U/L) 240.2 ± 67.8a 29.7 ± 11.0
TBiL (μmol/L)# 19.3 ± 8.8a 14.4 ± 4.9
ALB (g/L)# 44.3 ± 1.8 47.3 ± 2.7
HBV DNA (log10 cps/ml)§ 8.91 ± 0.56 4.07 ± 1.32
HBsAg (log10 IU/ml) 4.15 ± 0.53 3.15 ± 0.25**
HBV genotype 5B, 4C -
These values expressed as mean ± SD, unless otherwise indicated.
Normal values: ALT, ≤ 48 U/L; TBiL, ≤ 22 μmol/L; ALB, 32 ~ 50 g/L.
*P <0.05, comparing with week 24; **P <0.001, comparing with baseline; ▲P >0.05,
§P <0.001, among SC or non-SC groups; #P >0.05, among SC or non-SC groups.
aP <0.001, comparison between SC and non-SC groups at baseline.
ALT, alanine transaminase; ALB, albumin; DNA, deoxyribonucleic acid; HBV, hepatitis
SC, HBeAg seroconversion.
All subjects were of Chinese Han ethnicity.progressive reduction in HBsAg levels during therapy
compared to the baseline (Figure 2A). However, a fluctu-
ating decline in HBsAg and ALT levels was observed in
non-SC patients (Figure 2B). Moreover, SC patients
showed a significant correlation between changes inine, 24W and 72W
Non-SC
72W Baseline 24W 72W
- 34.4 ± 9.1 - -
- 9/2 - -
19.4 ± 9.0* 156.7 ± 41.9a 48.2 ± 23.4 48.6 ± 35.9▲
12.7 ± 4.7 13.1 ± 3.7a 14.4 ± 3.2 11.6 ± 4.3
47.3 ± 0.7 45.3 ± 2.1 48.3 ± 3.3 47.4 ± 3.2
2.1 ± 0.04 8.46 ± 0.73 4.06 ± 1.30 2.53 ± 0.50
2.93 ± 0.42 3.86 ± 0.91 3.43 ± 0.73▲ 3.16 ± 0.41
- 7B, 4C - -
comparing with baseline or week 24.
B virus; TBiL, Total bilirubin; −, useless; non-SC, non HBeAg seroconversion;
Figure 2 Association between HBsAg or HBeAg and ALT levels in SC or non-SC patients during treatment. The relationship between
serum HBsAg (log10 IU/ml) and ALT (U/L) level is shown for SC (A) and non-SC patients (B). The relationship between serum HBeAg (log10 S/CO)
and ALT (U/L) level is shown for SC (C) and non-SC patients (D). Correlations were analyzed using Spearman correlation analysis.
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cant correlation was observed in the non-SC group,
however (R = 0.226, P = 0.559).
In a manner similar to the association between serum
HBsAg and ALT levels in the non-SC group, the HBeAg
level declined in SC-patients during the course of treat-
ment along with ALT, and there was no significant rela-
tionship between them (R = 0.812, P = 0.050; Figure 2C).
A similar relationship was found in the non-SC group as
well (R = 0.617, P = 0.077; Figure 2D).
The relationship between serum HBsAg and HBeAg and
circulating HBV DNA levels in SC and non-SC patients
As was the case for the association between serum
HBsAg and ALT levels in the SC group, the HBsAg level
declined along with HBV DNA in the SC group over the
course of treatment, and there was a significant relation-
ship between them (R = 0.964, P < 0.001; Figure 3A).
However, a significant positive relationship was not
observed in non-SC patients (R = 0.527, P = 0.145;
Figure 3B). In addition, in the SC group, no HBeAg
could be detected after week 60, and no HBV DNA
could be detected after week 72. Furthermore, there was a
significant relationship between these two parameters(R = 0.899, P = 0.015; Figure 3C). In non-SC patients
undergoing TDF treatment, the fluctuating reduction in
HBV DNA loading was concurrent with a stable decline
in HBeAg, and there was significantly relationship be-
tween these two parameters as well (R = 0.900, P < 0.001;
Figure 3D).
A significant correlation was observed between HBsAg
(log10 IU/ml) and HBV DNA (log10 copies/ml) in all
HBeAg-positive patients (SC and non-SC patients) at
baseline, but no significant correlation was observed at
week 24 (Additional file 3: Figure S3). Simultaneously, a
significant correlation between HBsAg and HBV DNA
loading was a prominent discrepancy between SC and
non-SC patients at baseline (Additional file 4: Figure S4).
The relationship between serum HBsAg and HBeAg levels
and circulating Treg frequencies in SC and non-SC patients
As was observed with the changing of serum HBsAg
levels associated with HBV DNA loading, circulating
Treg frequencies showed a very steady decline along
with the HBsAg level decline in the SC group during
TDF treatment, and there was a significant relationship
between these two parameters (R = 0.900, P = 0.001;
Figure 4A). However, in the non-SC group, the Treg
Figure 3 Association between HBsAg or HBeAg and HBV DNA level in SC or non-SC patients during treatment. The relationship between
serum HBsAg (log10 IU/ml) and HBV DNA level (log10 copies/ml) is shown for SC (A) and non-SC patients (B). The relationship between
serum HBeAg (log10 S/CO) and HBV DNA level (log10 copies/ml) is shown for SC (C) and non-SC patients (D). Correlations were analyzed
using Spearman correlation analysis.
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tion in the HBsAg level during treatment, and the turn-
ing point for the declining HBsAg level was observed at
week 12. In addition, there was no significance between
HBsAg and HBV DNA loading (R = 0.611, P = 0.081;
Figure 4B).
As was the case for changes in the serum HBsAg level,
the Treg frequencies declined along with a decline in the
HBeAg level during treatment of patients in the SC
group, and there was a significantly relationship between
the two parameters (R = 0.899, P = 0.015; Figure 4C).
Similarly, there was a significant difference between the
circulating Treg frequency and the HBeAg level in the
non-SC group as well (R = 0.967, P < 0.001; Figure 4D).
The relationship between serum HBsAg and HBeAg levels
in SC and non-SC patients
We observed a significant positive correlation between
HBsAg and ALT, HBV DNA loading, and Treg frequen-
cies (P < 0.001, P < 0.001, or P = 0.001, respectively) in
SC patients during the TDF therapy period. We also ob-
served a significant positive relationship between HBsAg
and HBeAg (R = 0.986, P < 0.001; Figure 5A). However, asignificant relationship was not present in non-SC pa-
tients (R = 0.644, P = 0.061; Figure 5B). Furthermore,
there was no significant relationship between HBsAg
and HBeAg in any patients prior to antiviral treatment
(data no shown).
Discussion
Measurement of serum HBV DNA loading remains as im-
portant tool for monitoring antivral treatment outcomes
for CHB patients who do not always experience SC,
although they have undergone with potently suppress HBV
replication, followed by treatment with regular antiviral
treatment [17-19]. However, HBsAg clearance from the
serum of CHB patients usually indicates clinical cure and is
associated with improved survival. In recent years, increas-
ing attention has been paid to the quantitation of HBsAg
and the use of this knowledge in the antiviral treatment of
CHB patients [12,20,21]. The present study indicated that
quantitated HBsAg serves as a useful marker for response
to antiviral therapy in SC and non-SC patients during TDF
treatment.
At present, HBsAg has been developed as an alterna-
tive marker for the monitoring of antiviral treatment
Figure 4 Association between HBsAg or HBeAg and Treg frequencies in SC or non-SC patients during treatment. The relationship
between serum HBsAg (log10 IU/ml) level and circulation CD4+CD25+ Treg frequency is shown for SC (A) and non-SC patients (B). The
relationship between serum HBeAg (log10 S/CO) level and circulation CD4+CD25+ Treg frequency is shown for SC (C) and non-SC patients
(D). Correlations were analyzed using Spearman correlation analysis.
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duction does not correlate closely with viral replication
because it depends on transcriptional activities involving
other enzymatic factors [23]. The production of HBsAg
is in excess to whole virions (HBV Dane particles) be-
cause serum HBsAg includes two other elements (small
spherical and tubular particles). Therefore, the correl-
ation between HBV DNA and HBsAg levels may be
imbalanced, indicating that antiviral therapy does not
directly influence the serum HBsAg level under some
conditions [22].
In the current study, our results are consistent with
the hypothesis that there was no significant correlation
between serum HBsAg and HBV DNA levels in all
HBeAg positive patients over the course of TDF treat-
ment, however, there was a different significant correl-
ation during antiviral treatment when the relationship
between HBsAg and HBV DNA levels were analyzed
separately in SC and non-SC patients, respectively. The
correlation for SC patients was significant, while the cor-
relation for non-SC patients was not. These results sug-
gested that serum HBsAg levels could reflect the HBV
DNA level in undergoing SC CHB patients during TDFtreatment, which is consistent with the hypothesis that
quantitative serum HBsAg has a high predictive value
for treatment response towards IFNα-1b or entecavir
[21,24]. Furthermore, the relationships between HBeAg
and ALT (HBV DNA, or Tregs) in SC or non-SC pa-
tients during treatment were similar statistical relation-
ship (both are significant relationship or not), which
suggests that quantitative HBsAg is a more useful indi-
cator than HBeAg for distinguishing between SC and
non-SC patients during TDF treatment. This is in con-
trast to Singh, A. et al’s findings that indicated that the
HBsAg decline did not correlate with HBeAg serocon-
version in HBeAg-positive patients, and reduction in
HBV DNA levels at week 4 and 12 correlated with sero-
conversion [25]. This difference may be related to the
opinion that the variable pattern and clinical outcome of
HBV infection were mainly determined by virological
itself factors, host immunological factors and genetic
factors of host [26].
Additionally, the positive relationship between HBsAg
and ALT levels was significant in SC but not in non-SC
patients, further indicating the importance of analyzing
HBsAg levels during TDF treatment.
Figure 5 Association between HBsAg and HBeAg in SC or non-SC
patients during treatment. The relationship between serum HBsAg
(log10 IU/ml) and HBeAg (log10 S/CO) level is shown for SC (A) and
non-SC patients (B). Correlations were analyzed using Spearman
correlation analysis.
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positive CHB patients subjected to antiviral treatment,
and the SC process is affected by many factors. Our re-
sults showed that SC patients had a significantly higher
serum ALT level at baseline than did non-SC patients
(Table 1), which was partially consistent with Tseng’s re-
port that a higher serum ALT level correlated with earl-
ier SC in lamivudine-treated chronic hepatitis B patients
[27]. In addition, we also discovered that the serum TBiL
level at baseline was higher in SC than in non-SC pa-
tients (Table 1).
It is generally believed that serum ALT levels reflect
the host immune response to chronic HBV infection,
and higher ALT levels indirectly indicate that SC pa-
tients are more readily restored to effective immune
function than non-SC patients. An intensive immune re-
sponse is quickly restored after HBV replication has
been inhibited during antiviral treatment, reducing dam-
age to liver cells and restoring serum ALT levels to nor-
mal [28-30]. In our study, the ALT level rapidly declined
to a normal level (<46 U/L) at week 12 in SC patients
during treatment, but did not in non-SC patients, which
most likely correlates with the significant decline in HBsAg
that was observed in CHB patients with preexistingimmune activity, as was reflected by high baseline ALT
levels [11,31,32]. Although, the HBsAg level in non-SC pa-
tients was depressed at the beginning of treatment, these
levels rebounded over the course of treatment.
Tregs play a key role in the maintenance of immune
tolerance and regulation of the immune response [33].
Tregs numbers typically increase in CHB patients and
are restored to normal levels in recovered CHB patients
subjected to antiviral treatment [34]. The results of this
study showed a significant positive correlation between
HBsAg and Treg levels in SC patients during treatment,
which further confirms that a reduction in Treg num-
bers is related to the process of SC, and patients who
did not achieve SC may be associated without being re-
stored to normal Treg numbers.
The immune mechanisms involved in SC are still not
fully understood. A high HBeAg level is believed to in-
duce T-cell tolerance or hyporesponsiveness [35]. During
antiviral treatment, specific enhancement of the cellular
immune response is indirectly caused by the suppression
of HBV replication and a reduction in the HBeAg anti-
gen level, rather than as a direct effect of any particular
drug. In addition, it has been reported that even high
concentrations of entecavir had no significant effect on
the survival and function of immune cells in vitro [36],
and antiviral therapy can promote a reduction in higher
PD-1 levels caused by a high HBeAg level and thus ele-
vate the level of HBV-specific CTL [37]. In this study,
serum HBsAg levels began to decline in response to
anti-viral treatment, and hence circulating Tregs were
restored to normal levels. This process reduced the in-
hibitory affect on antigen-specific T cells and promoted
HBeAg SC process. These results confirmed previous
observations that immune modulation is of vital import-
ance for the complete eradication of HBV and HBeAg
seroconversion [38,39]. In addition, the significant posi-
tive relation between HBsAg and HBeAg levels in SC
but not in non-SC patients during antiviral treatment
further implies that quantitating HBsAg is more import-
ance for the determination of seroconversion status
during TDF treatment, and HBsAg may be an immuno-
modulatory molecule over the course of CHB [40].
Limitations for this study include a short follow-up
period and the fact that none of SC patients lost HBsAg.
Therefore, the predictive value of quantitating HBsAg
levels for antiviral treatment-induced HBsAg seroconver-
sion could not be evaluated. Previous studies have shown
that HBsAg suppression in response to interferon-based
regimens may be predictive of subsequent HBsAg clearance
and seroconversion [10,41]. However, only a minority of
interferon-treated patients lose their HBsAg. One possible
explanation for the difference in HBsAg kinetics is that
PEG-IFN has a remarkable immune regulatory effect and
TDF has significant effects on viral replication, but a
Yang et al. Journal of Translational Medicine 2014, 12:183 Page 8 of 9
http://www.translational-medicine.com/content/12/1/183minimal effect on the immune response [12]. Therefore, it
may take longer for the host to re-initiate the immune re-
sponse and demonstrate a decline in the HBsAg level.
These results indirectly verified that long-term antiviral
therapy is very necessity for patients with CHB, and suggest
that the HBsAg level is closely association with the immune
status of CHB patients [40].
Another limitation of our study is that our patient
cohort was small, cccDNA levels, and baseline drug-
resistance mutational analysis were not measured, sim-
ultaneously. Indeed, cccDNA may become the dominant
form of HBV DNA during viral suppression with ente-
cavir and may be responsible for ongoing production
of HBsAg [42]. Reijnders, J. et al.’s multivariate analysis
showed that a decline in HBsAg was only related to the
treatment regimen (P <0.001) and not to any other
baseline variable [10].Conclusions
In summary, without considering the factor of 58 of the
78 patients dropped out in this study, close to half of
patients treated with TDF for 96 weeks achieved SC be-
tween weeks 24 to 72. A significant, early decline in HBsAg
at 12 weeks was associated with higher rates of complete
HBV DNA suppression and SC during the TDF treatment
period. Therefore, the quantitation of HBsAg is a more use-
ful indicator than HBeAg for distinguishing SC from non-
SC patients during TDF treatment.Additional files
Additional file 1: Figure S1. Changing HBsAg level in SC and non-SC
patients during treatment. Serum HBsAg (log10 IU/ml) level in SC and non-SC
patients during TDF treatment for 96 weeks was shown, respectively.
Additional file 2: Figure S2. HBsAg varying at baseline and week 12
in SC and non-SC patients during treatment. The serum HBsAg level
(log10 IU/ml) was compared between at baseline and week 12 in SC
and non-SC patients during treatment, respectively.
Additional file 3: Figure S3. The association between HBsAg and HBV
DNA level in all HBeAg positive patients. The relationship between serum
HBsAg (log10 IU/ml) and HBV DNA (log10 copies/ml) level in all HBeAg
positive patients is shown at baseline (A) and week 24 during treatment (B).
Additional file 4: Figure S4. The association between HBsAg or HBV
DNA levels in SC or non-SC patients at baseline. The relationship between
serum HBsAg (log10 IU/ml) and HBV DNA (log10 copies/ml) level is
shown for SC (A) and non-SC patients (B) at baseline.Abbreviations
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